Synta therapy slows spread of melanoma

Lexington, MA-based Synta Pharmaceuticals caused quite a stir with a recent presentation on an early-stage cancer therapy that slowed the spread of aggressive skin cancer. In the Phase IIb trial, researchers said that cancer patients taking Synta's therapy survived 3.7 months without the appearance of new cancer lesions--compared to 1.8 months for patients taking standard therapy. The therapy adopts a new approach in cancer; killing cancer cells by overloading them with oxygen. Normal cells can adjust to higher oxygen levels. Advanced melanoma is a particularly lethal disease, killing 7 out of 10 patients in the first year. A bigger study involving 600 patients is being planned. Synta was a 2004 Fierce 15 Company.

- see Synta's release on the data

Related Articles:
Synta gets fast track for cancer therapy. Report
Synta trial hits endpoint. Report
Synta Pharmaceuticals Files For $115 IPO. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.